Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Science Track

Lung invasive fungal infection (IFI) in acute myeloid leukemia (AML) patients: role of 18-FDG-PET/CT

Federica Elisei, Lucia Baratto, Cinzia Crivellaro, Elena De Ponti, Luisa Verga, Francesca Farina, Merilena Fedele, Carlotta Dolci, Luca Guerra and Claudio Landoni
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1621;
Federica Elisei
3Department of Nuclear Medicine San Gerardo Hospital Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Baratto
7Department of Nuclear Medicine University of Milan-Bicocca Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cinzia Crivellaro
5Department of Nuclear Medicine - Tecnomed Foundation San Gerardo Hospital - University of Milan-Bicocca Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena De Ponti
2Department of Medical Physics San Gerardo Hospital Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa Verga
1Department of Haematology San Gerardo Hospital Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Farina
1Department of Haematology San Gerardo Hospital Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merilena Fedele
6Department of Haematology University of Milan-Bicocca Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlotta Dolci
8Tecnomed Foundation University of Milan-Bicocca Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Guerra
3Department of Nuclear Medicine San Gerardo Hospital Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudio Landoni
4Department of Nuclear Medicine San Gerardo Hospital - University of Milan-Bicocca Monza Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1621

Objectives To evaluate the role of FDG PET/CT with respect to conventional CT scan, in acute myeloid leukemia (AML) patients with lung invasive fungal infection (IFI).

Methods 14 patients with AML and suspected lung IFI performed chest CT scan (CT1) followed by PET/CT (PET1) scan, before antimicotic treatment. CT and PET/CT were repeated 2 months after the beginning of treatment (n= 12 pts) and compared to basal evaluations to assess treatment efficacy (CT2, PET2): lesions with the highest FDG uptake on PET was selected as “reference lesion” and SUVmax was calculated for PET1 and PET2. Metabolic response (MR) was measured as follow: complete MR (CMR, uptake ≤ than mediastinal blood-pool), partial MR (PMR, partial reduction of the lesion uptake > than mediastinal blood-pool), progressive disease (PD, increase uptake and/or new lesions).

Results : In 14/14 cases (100%) PET1 and CT1 were positive for IFI. The mean SUV max was 6.5 ± 2.4 (range 3.3-11.8). PET2 (n = 12) showed 4 CMR, 4 PMR, (with a mean reduction of SUVmax 53%), 2 PD and 2 with both PMR of reference lesion and concomitant new PD lung lesions with FDG uptake (PR/PD). In the same group of 10 patients, CT2 was concordant with PET2 in 10/12 cases (83%), while in 2 cases CT2 showed partial reduction of lung lesions and a CMR on PET2. Of the 10 concordant patients, 5 died because of infections (2PMR, 2PD, 1 both PMR/PD), and 5 are alive, median follow-up 356 days from PET/CT1, (2 CR, 2 PR and 1 PR/PD). Of the 2 discordant patients 1 died because of sepsis, and 1 patient is on follow-up (150 days).

Conclusions PET/CT scan can help in monitoring treatment efficacy of IFI in AML patient. However, as PET/CT and CT were concordant in 83% of cases (10/12), while in 2 cases PET/CT showed a complete metabolic response in a persistent lung lesion at CT, these preliminary data cannot support a relevant additional role of PET with respect to CT scan; further follow-up and larger studies are needed.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lung invasive fungal infection (IFI) in acute myeloid leukemia (AML) patients: role of 18-FDG-PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Lung invasive fungal infection (IFI) in acute myeloid leukemia (AML) patients: role of 18-FDG-PET/CT
Federica Elisei, Lucia Baratto, Cinzia Crivellaro, Elena De Ponti, Luisa Verga, Francesca Farina, Merilena Fedele, Carlotta Dolci, Luca Guerra, Claudio Landoni
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1621;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lung invasive fungal infection (IFI) in acute myeloid leukemia (AML) patients: role of 18-FDG-PET/CT
Federica Elisei, Lucia Baratto, Cinzia Crivellaro, Elena De Ponti, Luisa Verga, Francesca Farina, Merilena Fedele, Carlotta Dolci, Luca Guerra, Claudio Landoni
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1621;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Science Track

  • Clinical value of 68Ga-DOTATATE PET/CT in the evaluation of recurrent medullary thyroid cancer patients.
  • The diagnostic performance and added value of 18F-NaF PET/CT in the detection of bone metastases in patients with nasopharyngeal carcinoma
  • Prognostic value of pre-treatment 18F-FDG PET/CT volumetric parameters in patients with locally advanced larynx carcinoma.
Show more Oncology, Clinical Science Track

MTA I: Leukemia/Lymphoma/Myeloma Posters

  • Role of 18F-FDG PET/CT in the management of patients with primary breast lymphoma.
  • Prospective Comparison of 11C-4DST, 18F-FDG PET/CT and whole-body MRI in the patients with multiple myeloma
Show more MTA I: Leukemia/Lymphoma/Myeloma Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire